Experimental drug duo targets Hard-to-Treat cancers

NCT ID NCT05293496

Completed Disease control Sponsor: MacroGenics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants received the drugs every 4 weeks for up to 2 years, with regular tumor scans to see if the cancer shrank.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vobramitamab duocarmazine (MGC018) and lorigerlimab (MGD019)
What this could lead to: If successful, this could point toward a new combination treatment for several advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early, small Phase 1 trial with only 31 participants, so safety and dosing are the main focus. The combination may not shrink tumors or could cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial castration-resistant prostate carcinoma hepatocellular carcinoma Liver Neoplasms malignant pancreatic neoplasm melanoma metastatic prostate carcinoma neoplasm ovarian cancer ovarian carcinoma pancreatic ductal adenocarcinoma pediatric hepatocellular carcinoma Prostatic Neoplasms, Castration-Resistant renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR CASTRATION RESISTANT PROSTATIC CANCER EPITHELIAL OVARIAN CANCER HEPATOCELLULAR CANCER MALIGNANT MELANOMA PANCREATIC DUCTAL CARCINOMA RENAL CELL CARCINOMA

Contacts and locations

Locations

Carolina BioOncology

Huntersville, North Carolina, 28078, United States
Florida Cancer Specialists and Research Institute

Sarasota, Florida, 34232, United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, 21287, United States
Stephenson Cancer Center, The University of Oklahoma

Oklahoma City, Oklahoma, 73104, United States
University of California, Los Angeles

Los Angeles, California, 90095, United States
University of California, San Francisco

San Francisco, California, 94115, United States
University of Pittsburgh Medical Center, Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
University of Virginia Comprehensive Cancer Center

Charlottesville, Virginia, 22908, United States
Weill Cornell Medicine

New York, New York, 10065, United States
Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.